Abstract
Introduction
Early diagnosis and treatment of thyroid eye disease (TED) improves outcomes. Previous studies have highlighted delays in diagnosis and referral to specialist centres. The Amsterdam declaration (2009) aimed to halve the time from presentation to diagnosis and from diagnosis to referral to a specialist centre in five years. A recent study from the European group on Graves’ orbitopathy tertiary centres showed a trend for earlier referral of patients to the centres. It is unknown whether similar improvements are occurring in secondary care hospitals in the UK.
Aim
To study the trend in referral to a UK secondary care specialist TED clinic since the Amsterdam declaration.
Methods
We carried out a prospective audit of patients who attended the specialist TED clinic after the Amsterdam declaration (2010–2015). We compared their clinical characteristics, including duration of symptoms, disease activity and severity, with those of the patients (n = 114) from an earlier audit attending the clinic during 2004–2008.
Results
During 2010–2015, 126 patients with TED (97 females, median age 55 years, 39 current smokers) attended the clinic. The median time from onset of symptoms to being seen in the clinic was 5 months, reduced from 12 months in 2004–2008 (p < 0.001). As compared to the 2004–2008 cohort, significantly more patients in the current cohort presented with mild disease (72 vs. 52%, p = 0.002). Twenty-seven per cent patients had active TED (clinical activity score ≥3/7) compared to 18% in 2004–2008 (p = 0.1).
Conclusions
The trend in referral to secondary care specialist TED clinic is changing in line with the Amsterdam declaration aims.
Similar content being viewed by others
References
Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560
Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362(8):726–738
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4):1443–1449
Estcourt S, Quinn AG, Vaidya B (2011) Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol 164(5):649–655
Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ (2013) Public health relevance of Graves’ orbitopathy. J Clin Endocrinol Metab 98(1):145–152
Wiersinga WM (2016) Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol S2213–8587(16):30046–30048
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) European Group on Graves’ Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285
Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B (2009) The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol 161(3):483–487
Prummel MF, Bakker A, Wiersinga WM et al (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European group on Graves’ orbitopathy experience. Eur J Endocrinol 148:491–495
Sasim IV, Berendschot TT, van Isterdael C, Mourtis MP (2008) Planning health care for patients with Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 246:1315–1321
The Amsterdam Declaration (2010) Graves’ orbitopathy: improving outcomes for thyroid eye disease—the Amsterdam declaration. Thyroid 20(3):351–352
Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Ćirić S, Daumerie C, Eckstein A, Fichter N, Führer D, Hegedüs L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Currò N, Dayan C, Dickinson J, Knežević M, Lane C, Marcocci C, Marinò M, Möller L, Nardi M, Neoh C, Pearce S, von Arx G, Törüner FB (2015) PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group on Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99(11):1531–1535
Benzimra JD, Quinn AG, Kersey T, McGrane D, Goss L, Vaidya B (2014) Management of patients in a combined thyroid eye clinic in secondary care. Int Ophthalmol 34(1):1–6
The European Group on Graves’ Orbitopathy (EUGOGO) (2016) (http://www.eugogo.eu/downloads.html). Accessed 26 Nov 2016
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European thyroid association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5(1):9–26
The UK thyroid eye disease Amsterdam declaration implementation group (TEAMeD) (2016) (http://www.btf-thyroid.org/projects/teamed). Accessed 26 Nov 2016
Perros P, Dayan CM, Dickinson AJ, Ezra D, Estcourt S, Foley P, Hickey J, Lazarus JH, MacEwen CJ, McLaren J, Rose GE, Uddin J, Vaidya B (2015) Management of patients with Graves’ orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clin Med (Lond) 15(2):173–178
Mitchell AL, Goss L, Mathiopoulou L, Morris M, Vaidya B, Dickinson AJ, Quinn A, Dayan C, McLaren J, Hickey JL, Lazarus JH, Rose GE, Foley P, MacEwen CJ, Perros P (2015) Diagnosis of Graves’ orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists. J Clin Endocrinol Metab 100(3):E458–E462
Mitchell AL, Zammitt N, Ajjan R, Vaidya B, Hickey J, Perros P, Dayan C (2016) Increasing awareness of Graves’ orbitopathy with “Early warning” cards—a TEAMeD multicentre quality improvement project. Endocr Abstr 44:P236
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves’ Orbitopathy (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364(20):1920–1931
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Quinn, A.S., Dujardin, L.R., Knight, B. et al. Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration. Int Ophthalmol 38, 301–306 (2018). https://doi.org/10.1007/s10792-017-0463-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-017-0463-0